<?xml encoding="utf-8" ?> ACADIA Pharmaceuticals ACAD reported third-quarter financial results on Wednesday. The transcript ...

<?xml encoding="utf-8" ?> Vir Biotechnology VIR reported third-quarter financial results on Wednesday. The transcript from ...

Qure's AMT-130 data likely remains strong enough to support accelerated approval, which isn't priced into the stock at the ...

Reference file lists each ingredient in the BreathEaseX oral spray and its CardioEaseX companion capsule alongside the ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...

Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple ...

A Nature Medicine phase II study reports 70.1% MPR and 50.7% pCR with perioperative ivonescimab plus chemotherapy in ...

Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing ...

A study of 261 neonates in intensive care found that sleep apnea severity was generally similar in supine and nonsupine ...

A peptide is a short chain of amino acids, usually under fifty residues, that the body uses as a signaling molecule. Most ...

FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~~ ...